GILEAD SCIENCES, INC. - 26 Nov 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Reporting relationship: 10%+ Owner
Issuer ticker: XLO
Reported as of: 26 Nov 2025
Net transaction value: +$9,999,916
SEC form: 4
Accepted by SEC: 01 Dec 2025, 16:36:41 UTC
Prior SEC filing: 03 Oct 2025
Next SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson

Key filing fact

GILEAD SCIENCES, INC. filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 01 Dec 2025.

Key facts

This page summarizes GILEAD SCIENCES, INC.'s Form 4 filing for Xilio Therapeutics, Inc. (XLO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 01 Dec 2025, 16:36.

Change

Previous filing in this sequence was filed on 03 Oct 2025.
Current net transaction value: +$9,999,916.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000882095 Primary reporting owner

GILEAD SCIENCES, INC.

Relationship: 10%+ Owner
Address: 333 LAKESIDE DRIVE, FOSTER CITY
Signature: Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson
Signature date: 01 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XLO transaction Derivative

Prefunded Warrants (right to buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value: $9,999,916
Shares: +13,335,000
Change %: +57%
Price: $0.7499
Shares after: 36,645,266
Date: 26 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,335,000
Exercise price: $0.000100
Footnotes: F1, F2

XLO transaction Derivative

Series B Warrants (right to buy)

Exercise of in-the-money or at-the-money derivative security

Transaction value: $0
Shares: -13,335,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 26 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,335,000
Exercise price: $0.7499
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Reporting Person acquired 13,335,000 Prefunded Warrants upon the exercise of an equal number of Series B Warrants at an exercise price of $0.7499 per warrant. A holder of either such warrant may not exercise such warrant if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer (the "Common Stock").

Footnote F2

The Prefunded Warrants are exercisable at any time on or after the date of issuance and have no expiration date.

Footnote F3

The exercise price of the Series B Warrants was $0.75 per share of Common Stock. Because the Reporting Person chose to receive Prefunded Warrants in lieu of Common Stock upon exercise of the Series B Warrants, the exercise price was $0.75 less $0.0001 per share.

Footnote F4

The Series B Warrants were exercisable at any time on or after November 1, 2025 and would have expired on December 2, 2025, provided that if the closing price of the Common Stock was below the exercise price on such date, the exercise price would have reset to the closing price on December 1, 2025 and the expiration time would have been extended to December 31, 2025.